Today's Must Read
Abbott (ABT) Thrives on New Tests launch Amid Covid-19 Mayhem
Investment in Renewable and Infrastructure Aid NextEra (NEE)
Wednesday, April 28, 2020
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Cisco’s shares have mildly outperformed the Zacks Computer Networking industry over the past year (-22.5% vs. -24%). The Zacks analyst believes that Cisco is benefiting from solid security business. Increasing demand for collaborative solutions, which includes Webex Teams, post the coronavirus outbreak is positive.
Moreover, a strong uptake of Catalyst 9000 family of switches and Nexus 9K solutions is a key catalyst. Integration with Microsoft Azure, Office 365 and Amazon Web Services is expected to fortify footprint in the cloud space.
Despite a grim third-quarter fiscal 2020 outlook, the company’s differentiated end-to-end approach across the network, cloud and endpoints is likely to be a key catalyst for the rest of fiscal 2020. However, lower customer spending, China-related weakness, and a growing global economic uncertainty due to the unabated spread of coronavirus are major headwinds.
Shares of Abbott have gained +9.4% over the past six months against the Zacks Medical Products industry’s fall of -5.7%. The Zacks analyst believes that Abbott’s Core Laboratory Diagnostics, cardiovascular and neuromodulation sales were significantly down in the first quarter of 2020 due to low demand in the past few months.
With the healthcare industry shifting its focus to control the coronavirus-led damage, Abbott has witnessed its molecular diagnostics and nutrition businesses putting up impressive performance during this period. The company launched three back-to-back diagnostic tests for covid-19.
Meanwhile, Abbott exited the first quarter of 2020 with better-than-expected earnings and revenue numbers. In the quarter, Abbott registered strong and consistent performance within EPD and Medical Devices segments. Abbott has been in news within Diabetic Care on growth with FreeStyle Libre.
NextEra’s shares have lost -13.4% over the past three months against the Zacks Electric Power industry’s fall of -15.9%. The Zacks analyst believes that the company is poised to benefit from the ongoing investments. Its “30 by 30” plan will help it meet the goal of making the generation portfolio cleaner.
The $50-$55B investment through 2022 will add more clean power generation units, and strengthen its infrastructure. The company has enough liquidity to counter the challenges posed by COVID-19. NextEra continued with its capital projects amid this crisis.
However, its nature of business is subject to complex and comprehensive federal, state and other regulations. If the planned nuclear plant outages last longer or an unplanned outage occurs, the company’s normal operations and profitability might be hindered.
Other noteworthy reports we are featuring today include Eli Lilly (LLY), Gilead Sciences (GILD) and Edwards Lifesciences (EW).
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>